source
- Stealthy biotech Treeline Biosciences to go public via reverse merger with Standard BioToolsTreeline Biosciences announced a plan to become a public company through a reverse merger with microfluidics firm Standard BioTools. The transaction will give Standard shareholders about 15.5% of…
- Merck, Gilead report mixed outcomes in key lung cancer, HIV studiesTrodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.